Literature DB >> 33720767

How Adults with Type 1 Diabetes Are Navigating the Challenges of Open-Source Artificial Pancreas Systems: A Qualitative Study.

Jasmine Schipp1,2,3, Timothy Skinner2,4,5, Edith Holloway1,2, Renza Scibilia6, Henriette Langstrup3, Jane Speight1,2, Christel Hendrieckx1,2.   

Abstract

Objective: An emerging group of people with type 1 diabetes are building and using their own artificial pancreas systems (APS). Currently, these "user-led," open-source systems are not endorsed by regulatory bodies. People face multiple challenges when building and using open-source APS (e.g., lacking required technical knowledge, difficulties sourcing hardware). We explored the experiences of adults with type 1 diabetes using open-source APS to understand how they are navigating these challenges. Research Design and
Methods: We conducted semistructured telephone interviews (October 2018 to January 2019) with Australian adults about their experiences using an open-source APS. Interviews were recorded, transcribed, and analyzed thematically.
Results: Participants included 23 adults with type 1 diabetes, aged 25-64 years, 10 (43%) women, with 1-34 months of experience of open-source APS. Participants used four key strategies to navigate challenges: (1) peer support, (2) self-sufficiency, (3) risk management, and (4) trade-offs. Participants relied on peer support and self-sufficiency to fill perceived gaps in professional and industry support. They felt that using an open-source solution was no riskier than previous management and demonstrated a conscious weighing-up of risks. Overall, participants felt that the experienced benefits for their physical health and quality of life outweighed the challenges and potential risks. Conclusions: Adults with type 1 diabetes are applying several interweaving psychosocial and practical strategies to navigate the challenges of building and using open-source APS. The findings highlight the importance of health professionals' showing support and understanding for those choosing to use an open-source APS.

Entities:  

Keywords:  Automated insulin delivery system; DIYAPS; Open-source artificial pancreas system (APS); Peer support; Psychosocial

Mesh:

Substances:

Year:  2021        PMID: 33720767     DOI: 10.1089/dia.2020.0652

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  5 in total

1.  Qualitative Study of User Experiences with Loop, an Open-Source Automated Insulin Delivery System.

Authors:  Sakinah C Suttiratana; Jessie J Wong; Monica S Lanning; Adrienne Dunlap; Sarah J Hanes; Korey K Hood; Rayhan A Lal; Diana Naranjo
Journal:  Diabetes Technol Ther       Date:  2022-05-12       Impact factor: 7.337

2.  Discontinued Use of the Loop Insulin Dosing System: A Mixed-Methods Investigation.

Authors:  Jessie J Wong; Sakinah C Suttiratana; Rayhan A Lal; John W Lum; Monica S Lanning; Adrienne Dunlap; Brandon Arbiter; Sarah J Hanes; Ryan J Bailey; Korey K Hood; Diana Naranjo
Journal:  Diabetes Technol Ther       Date:  2022-04       Impact factor: 7.337

3.  Device activism and material participation in healthcare: retracing forms of engagement in the #WeAreNotWaiting movement for open-source closed-loop systems in type 1 diabetes self-care.

Authors:  Bianca Jansky; Henriette Langstrup
Journal:  Biosocieties       Date:  2022-04-22

4.  Emotional and Physical Health Impact in Children and Adolescents and Their Caregivers Using Open-source Automated Insulin Delivery: Qualitative Analysis of Lived Experiences.

Authors:  Katarina Braune; Niklas Krug; Christine Knoll; Hanne Ballhausen; Axel Thieffry; Yanbing Chen; Shane O'Donnell; Klemens Raile; Bryan Cleal
Journal:  J Med Internet Res       Date:  2022-07-14       Impact factor: 7.076

Review 5.  A scoping review of Do-It-Yourself Automated Insulin Delivery system (DIY AID) use in people with type 1 diabetes.

Authors:  Amy E Morrison; Kimberley Chong; Peter A Senior; Anna Lam
Journal:  PLoS One       Date:  2022-08-11       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.